GlassScriptPhysician profile
James T Mcnutt
NPI 1003898883
$27,162.07
in general payments reported to CMS, 2019-2025
73 companies · $4,459 in 2025
The $4,459 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,429 · 2020: $2,777 · 2021: $4,069 · 2022: $3,988 · 2023: $4,177 · 2024: $4,263 · 2025: $4,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,669.67 |
| Education | $229.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,368.84 | 2020-2025 | |
| Emd Serono, INC. | $1,298.93 | 2019-2025 | Mavenclad |
| Lilly USA, LLC | $1,247.98 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Pfizer INC. | $1,107.09 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,087.14 | 2019-2025 | |
| Celgene Corporation | $998.29 | 2020-2025 | Zeposia |
| Ucb, INC. | $949.92 | 2019-2025 | Fintepla, Rystiggo, Nayzilam |
| Merz Pharmaceuticals, LLC | $917.89 | 2021-2025 | Xeomin, Inbrija, Ampyra |
| Biogen, INC. | $913.26 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Mallinckrodt Hospital Products INC. | $891.53 | 2020-2025 | Acthar |
| Allergan, INC. | $814.12 | 2019-2022 | |
| Sk Life Science, INC. | $781.17 | 2020-2025 | Xcopri |
| Genzyme Corporation | $777.66 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $728.87 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $716.16 | 2020-2025 | Ultomiris |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcnutt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.